Atara Biotherapeutics Inc.
Organization details
- Legal name
- Atara Biotherapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Thousand Oaks
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ATRA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001604464
- EIN
- 46-0920988
- Wikidata ID
- Q21874220
Board of directors
-
Ameet Mallik · DirectorSince 2023
-
AnhCo Nguyen · Director · President and CEOSince 2024
- Since 2023
-
Brian N. Cherry · DirectorSince 2026
-
Carol Giltner Gallagher · DirectorSince 2023
-
Eric Dobmeier · DirectorSince 2023
-
Gregory Austin Ciongoli · DirectorSince 2024
-
James Huang · DirectorSince 2025
-
Jeremy Green · DirectorSince 2025
-
Maria Grazia Roncarolo · DirectorSince 2023
-
Matthew K. Fust · DirectorSince 2023
-
Nachiappan Subramanian · DirectorSince 2025
-
Pascal Touchon · Director · President and CEOSince 2023
-
William K. Heiden · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 10, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.9%
-
89.2%
-
98.6%
Board connections
10 of this board's directors also sit on 22 other boards. 22 are in the same sector.
-
Zymeworks Inc. Same sectorvia Brian N. Cherry and Gregory Austin Ciongoli
-
ADC Therapeutics SA Same sectorvia Ameet Mallik
-
Absci Corporation Same sectorvia Jeremy Green
-
Alaunos Therapeutics Inc. Same sectorvia James Huang
-
Connect Biopharma Holdings Limited Same sectorvia James Huang
-
Electra Therapeutics Inc. Same sectorvia Matthew K. Fust
-
Fate Therapeutics Inc. Same sectorvia Jeremy Green
-
Gossamer Bio Inc. Same sectorvia Gregory Austin Ciongoli
-
Jade Biosciences Inc. Same sectorvia Eric Dobmeier
-
Janux Therapeutics Inc. Same sectorvia Eric Dobmeier
-
Kyverna Therapeutics Inc. Same sectorvia Beth C. Seidenberg
-
Latigo Biotherapeutics Inc. Same sectorvia Beth C. Seidenberg
-
MacroGenics Inc. Same sectorvia William K. Heiden
-
Neumora Therapeutics Inc. Same sectorvia Matthew K. Fust
-
PMV Pharmaceuticals Inc. Same sectorvia Carol Giltner Gallagher
-
Progyny Inc. Same sectorvia Beth C. Seidenberg
-
REGENXBIO Inc. Same sectorvia Gregory Austin Ciongoli
-
Sagimet Biosciences Inc. Same sectorvia Beth C. Seidenberg
-
Shattuck Labs Inc. Same sectorvia Jeremy Green
-
Structure Therapeutics Inc. Same sectorvia Eric Dobmeier
-
Ultragenyx Pharmaceutical Inc. Same sectorvia Matthew K. Fust
-
Vera Therapeutics Inc. Same sectorvia Beth C. Seidenberg
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $5,744,249
- 2 purchases by 2 insiders
- Sold, last 12 months
- $3,853,738
- 18 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 4, 2026 | Brian N. Cherry Director | Open-market purchase | +104,166 | $9.60 | $999,994 |
| Aug 17, 2026 | AnhCo Nguyen Director, Officer (President and CEO) | Open-market sale | −5,062 | $8.08 | $40,901 |
| Jul 22, 2026 | Redmile Group, LLC Director | Option exercise | +195,211 | — | — |
| Jul 22, 2026 | Redmile Group, LLC Director | Shares withheld for tax | −60 | — | — |
| Jun 11, 2026 | Brian N. Cherry Director | Grant or award | +24,000 | — | — |
| Jun 9, 2026 | William K. Heiden Director | Grant or award | +12,000 | — | — |
| Jun 9, 2026 | Matthew K. Fust Director | Grant or award | +12,000 | — | — |
| Jun 9, 2026 | Gregory Austin Ciongoli Director, 10% owner, See Remarks | Grant or award | +12,000 | — | — |
| May 18, 2026 | AnhCo Nguyen Director, Officer (President and CEO) | Open-market sale | −5,241 | $9.13 | $47,850 |
| May 18, 2026 | Grant-Huerta Yanina Officer (Chief Accounting Officer) | Open-market sale | −2,414 | $9.13 | $22,040 |
| May 7, 2026 | James Huang Director, 10% owner | Open-market sale | −313,446 | $10.10 | $3,165,805 |
| May 7, 2026 | EcoR1 Capital, LLC 10% owner | Open-market purchase | +507,407 | $9.35 | $4,744,255 |
| Mar 17, 2026 | James Huang Director, 10% owner | Option exercise | +259,163 | — | — |
| Mar 17, 2026 | James Huang Director, 10% owner | Shares withheld for tax | −5 | $5.23 | $26 |
| Mar 9, 2026 | AnhCo Nguyen Director, Officer (President and CEO) | Grant or award | +81,100 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Atara Biotherapeutics Inc.
Who is the CEO of Atara Biotherapeutics Inc.?
Pascal Touchon is Atara Biotherapeutics Inc.'s President and CEO.
How many directors are on Atara Biotherapeutics Inc.'s board?
Atara Biotherapeutics Inc.'s board has 14 directors: Ameet Mallik, AnhCo Nguyen, Beth C. Seidenberg, Brian N. Cherry, Carol Giltner Gallagher, Eric Dobmeier, Gregory Austin Ciongoli, James Huang, Jeremy Green, Maria Grazia Roncarolo and 4 others.
Are Atara Biotherapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Atara Biotherapeutics Inc. insiders bought $5.7 million of shares in 2 purchases and sold $3.9 million of shares in 18 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="atara-biotherapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.